Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y. Mabuchi S, et al. Among authors: testa jr. Clin Cancer Res. 2004 Nov 15;10(22):7645-54. doi: 10.1158/1078-0432.CCR-04-0958. Clin Cancer Res. 2004. PMID: 15569997
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. Mabuchi S, et al. Among authors: testa jr. Clin Cancer Res. 2009 Sep 1;15(17):5404-13. doi: 10.1158/1078-0432.CCR-09-0365. Epub 2009 Aug 18. Clin Cancer Res. 2009. PMID: 19690197 Free PMC article.
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Mabuchi S, et al. Among authors: testa jr. Mol Cancer Ther. 2010 Aug;9(8):2411-22. doi: 10.1158/1535-7163.MCT-10-0169. Epub 2010 Jul 27. Mol Cancer Ther. 2010. PMID: 20663925 Free PMC article.
Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.
Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, Testa JR, Kimura T. Hisamatsu T, et al. Among authors: testa jr. Mol Cancer Ther. 2013 Jul;12(7):1367-77. doi: 10.1158/1535-7163.MCT-12-1185. Epub 2013 Apr 24. Mol Cancer Ther. 2013. PMID: 23615631 Free PMC article.
Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Sasano T, et al. Among authors: testa jr. Mol Cancer Res. 2015 Apr;13(4):795-806. doi: 10.1158/1541-7786.MCR-14-0314. Epub 2014 Dec 17. Mol Cancer Res. 2015. PMID: 25519148 Free PMC article.
443 results